Cargando…
COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus that is affecting the entire world population. The objective of this study was to analyze the repercussion of the disease in a group of patients at risk s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418905/ https://www.ncbi.nlm.nih.gov/pubmed/34598811 http://dx.doi.org/10.1016/j.transproceed.2021.07.054 |
_version_ | 1783748653033193472 |
---|---|
author | López-Vilella, Raquel Sánchez-Lázaro, Ignacio Trenado, Víctor Donoso Edo, Silvia Lozano Dolz, Luis Martínez Bonet, Luis Almenar |
author_facet | López-Vilella, Raquel Sánchez-Lázaro, Ignacio Trenado, Víctor Donoso Edo, Silvia Lozano Dolz, Luis Martínez Bonet, Luis Almenar |
author_sort | López-Vilella, Raquel |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus that is affecting the entire world population. The objective of this study was to analyze the repercussion of the disease in a group of patients at risk such as heart transplant recipients. METHODS: From February 2020 to February 2021, heart transplant recipients diagnosed with COVID-19 were consecutively included. The total number of transplant recipients in outpatient follow-up at that time was 381. Three levels of infection were determined: group A: asymptomatic patients or with trivial symptoms without the need for hospital admission (6 patients); group B: patients admitted to the hospital for respiratory symptoms (12 patients); and group C: patients with severe symptoms and need for admission to the critical care unit (2 patients). At each risk level, medical performance was different: group A: close control, no therapeutic modification; group B: reduction of calcineurin inhibitor and substitution of mycophenolate mofetil for everolimus; group C: reduction of calcineurin inhibitor and withdrawal of mycophenolate mofetil. RESULTS: The prevalence of infection in the series was 5.2%. Most patients admitted had a pathologic chest x-ray with fever, cough, dyspnea, or vomiting. The change in immunosuppression performed in patients in group 2 was well tolerated and there was no graft rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was 50% in group 2 and 100% in group 3. CONCLUSIONS: A significant number of transplant recipients will be affected by COVID-19 (5.3%). Management of the infection will depend on the severity of the infection and must be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiologic situation, and treatment of the infection. |
format | Online Article Text |
id | pubmed-8418905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84189052021-09-07 COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital López-Vilella, Raquel Sánchez-Lázaro, Ignacio Trenado, Víctor Donoso Edo, Silvia Lozano Dolz, Luis Martínez Bonet, Luis Almenar Transplant Proc Article BACKGROUND: Coronavirus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus that is affecting the entire world population. The objective of this study was to analyze the repercussion of the disease in a group of patients at risk such as heart transplant recipients. METHODS: From February 2020 to February 2021, heart transplant recipients diagnosed with COVID-19 were consecutively included. The total number of transplant recipients in outpatient follow-up at that time was 381. Three levels of infection were determined: group A: asymptomatic patients or with trivial symptoms without the need for hospital admission (6 patients); group B: patients admitted to the hospital for respiratory symptoms (12 patients); and group C: patients with severe symptoms and need for admission to the critical care unit (2 patients). At each risk level, medical performance was different: group A: close control, no therapeutic modification; group B: reduction of calcineurin inhibitor and substitution of mycophenolate mofetil for everolimus; group C: reduction of calcineurin inhibitor and withdrawal of mycophenolate mofetil. RESULTS: The prevalence of infection in the series was 5.2%. Most patients admitted had a pathologic chest x-ray with fever, cough, dyspnea, or vomiting. The change in immunosuppression performed in patients in group 2 was well tolerated and there was no graft rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was 50% in group 2 and 100% in group 3. CONCLUSIONS: A significant number of transplant recipients will be affected by COVID-19 (5.3%). Management of the infection will depend on the severity of the infection and must be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiologic situation, and treatment of the infection. Elsevier Inc. 2021-11 2021-09-06 /pmc/articles/PMC8418905/ /pubmed/34598811 http://dx.doi.org/10.1016/j.transproceed.2021.07.054 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article López-Vilella, Raquel Sánchez-Lázaro, Ignacio Trenado, Víctor Donoso Edo, Silvia Lozano Dolz, Luis Martínez Bonet, Luis Almenar COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital |
title | COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital |
title_full | COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital |
title_fullStr | COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital |
title_full_unstemmed | COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital |
title_short | COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital |
title_sort | covid-19 and heart transplantation. initial experience in a tertiary hospital |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418905/ https://www.ncbi.nlm.nih.gov/pubmed/34598811 http://dx.doi.org/10.1016/j.transproceed.2021.07.054 |
work_keys_str_mv | AT lopezvilellaraquel covid19andhearttransplantationinitialexperienceinatertiaryhospital AT sanchezlazaroignacio covid19andhearttransplantationinitialexperienceinatertiaryhospital AT trenadovictordonoso covid19andhearttransplantationinitialexperienceinatertiaryhospital AT edosilvialozano covid19andhearttransplantationinitialexperienceinatertiaryhospital AT dolzluismartinez covid19andhearttransplantationinitialexperienceinatertiaryhospital AT bonetluisalmenar covid19andhearttransplantationinitialexperienceinatertiaryhospital |